# A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

> **NCT00880399** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 328 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** orvepitant
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00880399
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03-01
- **Primary completion:** 2010-06-01
- **Final completion:** 2010-06-16
- **Target enrollment:** 328 (ACTUAL)
- **Why stopped:** To allow assessment of isolated events of seizure during program
- **Last updated:** 2017-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00880399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00880399, "A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00880399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*